Google will no longer sell Glass Enterprise smart glass, according to the company website. The decision marks the end of the most recognizable line of smart glasses, which first launched in 2013 for a whopping $1,500.
"Thank you for over a decade of innovation and partnership," read a message from Google. "As of March 15, 2023, we will no longer sell Glass Enterprise Edition. We will continue supporting Glass Enterprise Edition until September 15, 2023."
While Google pitched augmented reality (AR) glasses as a major innovation in consumer technology, it never gained mainstream popularity. The tech giant was more successful selling it to companies looking to use it for more specialized work purposes.
That pivot came in 2017, and an updated version of Glass Enterprise was released in 2019.
Existing units will continue working through September 15th. Then Google will no longer provide software updates.
What this means for the future of AR is unclear. No specific plans have been announced, but Google said it remains interested in the concept.
YouTube will offer creators a way to rejoin the streaming platform if they were banned for violating COVID-19 and election misinformation policies that are no longer in effect.
Lukas Alpert of MarketWatch explores how networks, brands, and ad buyers absorb the shockwaves when late‑night show hosts are suddenly cut — and brought back.
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Scott Trench, host of the BiggerPockets Money Podcast, explores how recent rate cuts, high borrowing costs, and mortgage rates are reshaping U.S. real estate.
